Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-L1 Gene Mutation”

44 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 44 results

Testing effectiveness (Phase 2)Looking for participantsNCT04585750
What this trial is testing

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Who this might be right for
Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more
PMV Pharmaceuticals, Inc 300
Early research (Phase 1)Study completedNCT01656642
What this trial is testing

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Genentech, Inc. 67
Testing effectiveness (Phase 2)UnknownNCT03491345
What this trial is testing

K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor

Who this might be right for
PD-L1 Positive Mutation TumorEBV Positive Mutation TumorMSI-H Mutation Tumor+1 more
Yonsei University 60
Not applicableUnknownNCT04191252
What this trial is testing

Genetic Mutation in Epithelial Ovarian Cancer

Who this might be right for
Epithelial Ovarian CancerNucleotide VariantCopy Number Variation+6 more
Lei Li 500
Testing effectiveness (Phase 2)Study completedNCT06501378
What this trial is testing

Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis

Who this might be right for
NSCLC Stage IV
Fudan University 40
Not applicableLooking for participantsNCT06634199
What this trial is testing

Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients

Who this might be right for
Non-small Cell Lung Cancer Stage IIIPDL1 Gene Mutation
Fundación GECP 50
Not applicableUnknownNCT04405661
What this trial is testing

Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC

Who this might be right for
NSCLC
Guangzhou Institute of Respiratory Disease 100
Testing effectiveness (Phase 2)UnknownNCT05534113
What this trial is testing

Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC

Who this might be right for
Non-small Cell Lung Cancer
The First Affiliated Hospital with Nanjing Medical University 38
Not applicableUnknownNCT05527808
What this trial is testing

A Single-arm Exploratory Study of Neoadjuvant Therapy

Who this might be right for
Lung Adenocarcinoma
Jun Liu 28
Not applicableLooking for participantsNCT07618936
What this trial is testing

Programmed Cell Death Ligand 1 PET/CT in Various PD-L1-Related Disease Patients

Who this might be right for
PD-L1 Gene MutationPD-L1 Gene AmplificationPD-L1-related Disease+1 more
Tianjin Medical University 500
Testing effectiveness (Phase 2)UnknownNCT06195683
What this trial is testing

Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.

Who this might be right for
Non-small Cell Lung CancerPDL1 Gene Mutation
Zhejiang Cancer Hospital 23
Testing effectiveness (Phase 2)Study completedNCT04426825
What this trial is testing

Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche 23
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05280626
What this trial is testing

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

Who this might be right for
Diffuse Large B-Cell Lymphoma
Innovent Biologics (Suzhou) Co. Ltd. 100
Early research (Phase 1)Study completedNCT02027961
What this trial is testing

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Who this might be right for
Melanoma
MedImmune LLC 68
Large-scale testing (Phase 3)Looking for participantsNCT06119581
What this trial is testing

First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungNeoplasm Metastasis
Eli Lilly and Company 1,264
Testing effectiveness (Phase 2)UnknownNCT05266937
What this trial is testing

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Who this might be right for
Metastatic Breast CancerTriple Negative Breast CancerPD-L1 Gene Mutation
Consorzio Oncotech 49
Testing effectiveness (Phase 2)WithdrawnNCT04754815
What this trial is testing

Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC

Who this might be right for
Non Small Cell Lung CancerAdvanced Lung Non-Small Cell CarcinomaPD-L1 Gene Mutation
Shirish Gadgeel
Testing effectiveness (Phase 2)UnknownNCT04940637
What this trial is testing

UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC

Who this might be right for
Lung CancerMesothelioma
University of Turin, Italy 70
Testing effectiveness (Phase 2)Looking for participantsNCT07655622
What this trial is testing

Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression

Who this might be right for
Non-Small-Cell Lung Cancer
Second Affiliated Hospital of Nanchang University 45
Testing effectiveness (Phase 2)Looking for participantsNCT06269211
What this trial is testing

Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Ruijin Hospital 29
Next Page